Stay Updated with the Latest Evaxion Biotech A/S EVAX News in Real Time
Find EVAX news now at Meyka AI. Stay informed with the latest Evaxion Biotech A/S stocks updates, including price news, market analysis, and expert insights.
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.
CSL Shares Jump 17% After FY26 Reset; Meyka Grades Stock B on August 19
CSL shares jumped 17% after reporting a AUD 10 billion write-down on Vifor but signaling recovery. FY2027 revenue expected flat, underlying earnings to grow 5%. Meyka grades CSL a B.
CSL Ltd Shares Rise 17.21% as Company Signals Flat FY2027 Revenue
CSL Ltd shares jumped 17.21% on August 18, 2026, despite the company posting a $2.6 billion net loss. Australia’s largest healthcare firm flagged flat revenue for FY2027 alongside a return to profit growth. Investors focused on the earnings outlook rather than the headline loss. The rally marked CSL’s biggest single-day gain since June 2001. CSL’s…
Miami-Dade Schools Close 9 Campuses as Villalobos Takes Helm July 29
Miami-Dade County Public Schools closes nine schools and consolidates others starting August 13. New Superintendent Rafael Villalobos takes over amid enrollment and budget challenges.
Dassault Systèmes (EPA: DSY) Shares Rise After Q2 Earnings Beat and Up to $2 Billion ArisGlobal AI Deal
Dassault Systèmes reported solid Q2 2026 results on July 23, alongside a major acquisition announcement. The French software maker posted total revenue of €1.56 billion, up 4% in constant currency. Non-IFRS diluted EPS climbed 8% to €0.31, while operating margin expanded to 30%. Dassault Systèmes also unveiled a deal to acquire life sciences software firm…
Q32 Bio (NASDAQ: QTTB) Jumps 60% on Strong 36-Week Clinical Data for Hair Loss Treatment
On 13 July 2026, Q32 Bio (NASDAQ: QTTB) became one of the biggest gainers in the biotech sector after its shares climbed about 60% on the back of positive 36-week Phase 2a clinical results for its experimental alopecia areata treatment, bempikibart. The latest data showed meaningful hair regrowth in patients with severe hair loss while…
Abivax Shares Jump 3.91% After $920 Million Stock Offering Grows Beyond Expectations
Abivax shares climbed 3.91% on Nasdaq on July 2, 2026, after the French biotech confirmed its $920 million American Depositary Share offering. Underwriters exercised their full option, pushing gross proceeds well past the original $600 million target. The ADS offering priced at $125.00 apiece on July 1. Abivax (Nasdaq: ABVX, Euronext Paris: ABVX) said the…
AlzeCure Shares Soar 71% to Highest Since 2022 on $2.2 Billion Alzheimer’s Drug Licensing Deal
AlzeCure shares surged 71% on June 30, 2026, reaching their highest level since early 2022 after the Swedish biotech company announced an Alzheimer’s drug licensing agreement valued at more than $2.2 billion, excluding royalties. The deal gives global development and commercialization rights to its lead candidate, ACD856, and marks a major milestone for the company….
Abivax Shares Soar 27% After Ulcerative Colitis Drug Shows Strong Results in Hard-to-Treat Patients
Abivax shares surged sharply after new clinical trial results for its ulcerative colitis treatment, obefazimod, showed strong performance in patients who previously failed standard therapies. The stock reaction reflects renewed investor confidence in the biotech pipeline and growing hopes for a breakthrough therapy in a difficult disease area. The move also comes at a time…